Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2007

Link Technologies to Manufacture and Sell PNA Monomers through Deal with PNA Inventor Group

  • Link Technologies and the PNA Inventor Group entered into a nonexclusive license agreement to allow Link Technologies to manufacture and sell monomers for peptide nucleic acid (PNA) synthesis worldwide under the PNA Inventor Group’s patents.

    Recent estimates predict that PNA synthesis will account for 10% of the global DNA synthesis market by 2010, a market presently worth $800 million and growing at over 10% per year, according to Link.

    Initially, Link says that it will be offering the preferred Fmoc/Bhoc protected PNA monomers. These monomers are compatible with commercial automated oligonucleotide, peptide, or combinatorial synthesizers. The company anticipates that these products will be available next month.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »